TLR5 and neoplasm: In summary, CAR133-NK92 cells armed with the TLR5 agonist, CBLB502, confer a new ability to mobilize immune cells and mediate an anti-tumor response to tumors that escape killing by CAR133-NK92 cells, which helps prevent tumor escape from CAR-T/NK cell immunotherapy.